NPI 1871379321: Open Payments
NPI 1871379321. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$322 in 16 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $17 · 2025 $322
Food & beverage: $322
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $73 |
| SHIELD THERAPEUTICS INC | 3 | $56 |
| Exact Sciences Corporation | 2 | $41 |
| Lilly USA, LLC | 2 | $41 |
| AstraZeneca Pharmaceuticals LP | 1 | $24 |
| SCPHARMACEUTICALS INC. | 1 | $19 |
| Amgen Inc. | 1 | $19 |
| ABBVIE INC. | 1 | $18 |
| Phadia US Inc. | 1 | $16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: Ozempic, ACCRUFER, WAINUA, ZEPBOUND, The Cologuard Plus Collection Kit, Cologuard Collection Kit, FUROSCIX, REPATHA.
